作者@article {Siddall1792 = {P。西达和m . j .堂兄弟和a . Otte和t .葛瑞斯r·钱伯斯和t·k·墨菲}title ={中部与神经性疼痛与脊髓损伤},体积={67}={10},页面= {1792 - 1800}= {2006},doi = {wnl.0000244422.45278 10.1212/01.。出版商ff} = {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:探讨中部普瑞巴林与脊髓损伤相关的神经性疼痛。首页方法:12周,多中心研究的患者随机要么flexible-dose普瑞巴林150到600毫克/天(n = 70)或安慰剂(n = 67),进行报价。病人被允许保留在现有的稳定的疼痛治疗。主要疗效变量是端点代表痛苦得分,来自患者{\ textquoteright}最后7天每天疼痛日记。关键二次端点包括疼痛应答率,SF-MPQ,睡眠干扰,情绪,和病人全球的变化。结果:平均基线与组疼痛评分是6.54和6.73在安慰剂组。意味着端点与组的疼痛评分较低比安慰剂组(4.62)(6.27;p \ < 0.001),疗效观察早在第一周和维护持续时间的研究。普瑞巴林的平均剂量后三星期的稳定阶段是460毫克/天。 Pregabalin was significantly superior to placebo in endpoint assessments on the SF-MPQ. The >=30\% and >=50\% pain responder rates were higher with pregabalin than placebo (p \< 0.05). Pregabalin was associated with improvements in disturbed sleep (p \< 0.001) and anxiety (p \< 0.05), and more patients reported global improvement at endpoint in the pregabalin group (p \< 0.001). Mild or moderate, typically transient, somnolence and dizziness were the most common adverse events. Conclusions: Pregabalin 150 to 600 mg/day was effective in relieving central neuropathic pain, improving sleep, anxiety, and overall patient status in patients with spinal cord injury.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/67/10/1792}, eprint = {//www.ez-admanager.com/content/67/10/1792.full.pdf}, journal = {Neurology} }